About one third of children thought to have peanut allergy were able to tolerate supervised doses in hospital oral food challenges across a ten-site Australian study led by the Murdoch Children's Research Institute and the National Allergy Centre of Excellence.

Professor Kirsten Perrett, program lead, said roughly 35 per cent of participants passed the challenge or tolerated all doses of peanut flour in the controlled setting. The finding suggests a significant share of diagnoses based on skin prick tests alone may overstate true allergy.

Arthur Cameron's case

Geelong infant Arthur Cameron was diagnosed after a skin prick test showed sensitivity. His family joined the research project and learned through the hospital challenge that he could tolerate peanut when introduced incrementally under medical supervision, a result that changed feeding plans at home.

Perrett stressed that parents must not attempt challenges alone. Every oral food challenge carries anaphylaxis risk requiring resuscitation equipment and trained staff. The trial's point is to refine national pathways, not to encourage kitchen experiments.

Ten paediatric public hospitals participated in the national collaboration.

Diagnosis pathways

Peanut allergy affects about one in 30 Australian children, one of the highest rates globally. Allergists often rely on skin prick and blood tests because challenges are resource intensive. False positives impose dietary restrictions, anxiety and epinephrine carriage for years.

Integrating challenges after positive screens could reduce unnecessary avoidance, but hospitals must fund staff time and observation beds. Perrett said researchers are examining how results might extend to other allergens if protocols prove safe at scale.

What changes next

National allergy strategy leaders will review whether guidelines should mandate challenge referrals for certain test scores. Insurers and state health departments will ask about cost offsets if fewer children need ongoing specialist care and emergency visits.

Schools and childcare centres rely on medical plans supplied by families. A revised diagnosis affects risk assessments for classmates and kitchen policies. Communication between hospitals and GPs must improve so paediatricians know which patients qualify for hospital challenges.

The study does not claim peanut allergy is harmless. It shows diagnosis is imperfect. For families like the Camerons in Geelong, better testing can remove a label that shaped every mealtime decision.

Health system load

Allergy clinics in Melbourne and Sydney report long waits for challenge appointments because each session ties up nursing staff for half a day. Positive trial results could justify Medicare items for selected patients, spreading costs across states rather than leaving families to pay privately.

Retailers label products as nut-free based on supplier declarations; a clearer diagnosis reduces precautionary bans that schools impose when uncertainty remains. Paediatricians said GPs need decision trees on when to refer positive skin tests straight to hospital challenges rather than advising lifelong avoidance by default.

Emergency departments still treat anaphylaxis episodes weekly; the trial does not reduce that burden overnight. It may stop some children entering the risk pool in the first place if testing pathways tighten.